Clinical role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine

Hepato-Gastroenterology

Volumn 52, Issue 66, 2005, Pages 1715-1721

  Tokunaga, Yukihiko ^a   Takahashi, Keichi ^a   Saito, Tohru ^a  

^a Japan Post   (Japan)

Author keywords

Colorectal cancer; Dihydropyrimidine dehydrogenase; Human; Immunohistochemistry; Thymidine phosphorylase

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL DERIVATIVE; MONOCLONAL ANTIBODY; THYMIDINE PHOSPHORYLASE; UFT;

ADULT; AGED; ARTICLE; CALCULATION; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SAMPLE SIZE; SENSITIVITY ANALYSIS; STATISTICAL MODEL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; VEIN;

ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COLECTOMY; COLORECTAL NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; THYMIDINE PHOSPHORYLASE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 28544436512     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Moertel CG: Chemotherapy for colorectal cancer. N Engl J Med 1994; 330:1136-1142.
2. Advanced Colorectal Cancer Meta-analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992; 10:896-903.
3. Kono H, Kara Y, Sugita S, Karube Y, Matsushima Y, Ishitsuka H: Activation of 5'-deoxy-5-flurorouridine by thymidine phosphorylase in human tumor tissues. Chem Pharm Bull 1983; 31:175-178.
4. Heggie GD, Sommadossi JP, Cross DS, Husster WJ, Diasio RB: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987; 47:2203-2206.
5. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidine synthetase, and thymidine phosphorylase. Clin Cancer Res 2000; 6:1322-1327.
6. Takenoue T, Kitayama J, Takei Y, Umetani N, Matsuda K, Nita ME, Hatano K, Tsuruo T, Nagawa H: Characterization of dihydropyrimidine dehydrogenase in immunohistochemistry in colon carcinoma, and correlation between immunohistochemical score and protein level or messenger RNA expression. Ann Oncol 2000; 11:273-279.
7. Mcleod HL, Sludden J, Murray GI, Keenen RA, Davidson AI, Park K, Koruth M, Cassidy J: Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours. Br J Cancer 1998; 77:461-465.
8. Monden T, Haba A, Amano M, Kanoh T, Tsujie M, Ikeda K, Izawa H, Ohnishi T, Sekimoto M, Tomita N, Okamura J, Monden M: PyNPase expression and cancer progression in the colorectum. Jpn J Surg 1998; 99:446-451.
9. Kono T, Nishida M, Inagaki N, Tanaka Y, Yoneda M, Kasai S: Development and characterization of 1C6-203, a new monoclonal antibody specific to the human thymidine phosphorylase. J Histochem Cytochem 2001; 49:131-137.
10. Tokunaga Y, Hosogi H, Hoppou T, Nakagami M, Tokuka A, Ohsumi K: Prognostic value of thymidine phosphorylase/PD-ECGF in advanced colorectal cancer after surgery: Evaluation with a new monoclonal antibody. Surgery 2002; 131:541-547.
11. Tokunaga Y, Nakagami M, Tokuka A, Ohsumi K: Prognostic effects of dihydropyrimidine dehydrogenase in advanced colorectal cancer after surgery: Immunohistochemistry using a new monoclonal antibody. Anticancer Res 2003; 23:1763-1768.
12. Japanese Research Society for Cancer of Colon and Rectum: General rules for clinical and pathological studies on cancer of colon, rectum, and anus. 5th Edition. Tokyo: Kanehara and Co. Ltd., 1994. (Jpn)
13. Hsu SM, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29:577-580.
14. Fox SB, Moghaddam A, Westwood M, Turley H, Bicknell R, Gatter KC, Harris AL: Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study. J Pathol 1995; 176:183-190.
15. Bobrow M, Harris TD, Shaughnessy KJ, Litt GJ: Catalyzed reporter deposition, a novel method of signal amplification: Application to immunoassays. J Immunol Meth 1989; 125:279-284.
16. Herman GE, Alfont EA: The taming of immunohistochemistry: The new era of quality control. Biotech Histochem 1991; 66:194-199.
17. Lee TE: Statistical methods for survival data analysis. 2nd Edition. New York: John Wiley & Sons, 1992.
18. Breslow NE, Day NE: Statistical methods in cancer research. Volume II: The design and analysis of cohort studies. IARC Sci Publ 1987; pp. 1-406.
19. Peters GJ, Laurensse E, Leyva A, et al: Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5'-deoxy-5-fluorouracil in relation to drug-metabolizing enzymes. Cancer Res 1986; 46:20-28.
20. Peters GJ, Groeningen CJ, Laurencsse EJ, Pinedo HM: A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa. Cancer 1991; 68:1903-1909.
21. Yasue K, Usami Y, Hashizume H, Suga S, Ina K, Horiuchi Y, Nagai H, Murata Y, Ohkita T: Metabolism of fluoropyrimidine in cancer patients (part II). Jpn J Clin Pharmacol Ther 1987; 18:689-698.
22. Metzger R, Danenberg K, Leichman CG, et al: High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 1998; 4:2371-2376.
23. Evrard A, Cuq P, Ciccolini J, Vian L, Cano JP: Increased cytotoxicity and by Stander effect of 5-fluorouracil and 5-deoxy-5-fluorouracil in human colorectal cancer cells transfected with thymidine phosphorylase. Br J Cancer 1999; 80:1726-1733.
24. Schwartz EL, Baptiste N, Megati S, Wadler S, Otter BA: 5-Ethoxy-2'-deoxyuridine, a novel substrate for thymidine phosphorylase, potentiates the antitumor activity of 5-fluorouracil when used in combination with interferon, an inducer of thymidine phosphorylase expression. Cancer Res 1995; 55:3543-3550.
25. Isshi K, Sakuyama T, Gen T, Nakamura Y, Kuroda T, Katuyama T, Maekawa Y: Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphorybosyl transferase activities with in vitro chemotherapy to 5-FU. Int J Clin Oncol 2002; 7:335-342.
26. Fujii R, Seshimo A, Kameoka S: Relationships between the expression of thymidine synthase, dehydropyrimidine dehydrogenase, and orotate phophorybosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma. Int J Clin Oncol 2003; 8:72-78.
27. Schwartz PM, Moir RD, Hyde CM, Turek PJ, Handeschumacher RE: Role of uridine phosphorylase in the anabosim of 5-fluorouracil. Biochem Pharmacol 1985; 34:3585-3589.
28. Cao D, Russel RL, Zhang D, Leffert JJ, Pizzorno G: Uridine phosphorylase (-/-) murine embryonic stem cells clarify the key role of this enzyme in the regulation of the pyrimidine salvage pathway and in the activation of fluoropyrimidines. Cancer Res 2002; 62:2313-2317.
29. Katsumata K, Tomioka H, Sumi T, Yamashita S, Takagi M, Kato F, Nakamura R, Koyanagi Y, Aoki T, Kato K: Correlation between clinicopathologic factors and kinetics of metabolic enzymes for 5-fluorouracil given to patients colon carcinoma by two different dosage regimens. Cancer Chemother Pharmacol 2003; 51:155-160.
30. Fukushima M, Nomura Y, Murakami Y, Shirasaka T, Aiba K: Analysis of phosphrylation pathway of 5-fluorouracil in human cancer cell. Jpn J Cancer Chemothera 1996; 6:721-731.
31. Uchida M, Nakamura T: Metabolism of 5-fluorouracil in tumor cell. Pur Pyrim Metab 1991; 15:122-129.
32. Mori K, Hasegawa M, Nishida M, Toma H, Fukuda M, Kubota T, Nagasue N, Yamana H, Hirakawa YS Chung K, Ikeda T, Takasaki K, Oka M, Kameyama M, et al: Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. Int J Oncol 2000; 17:33-38.
33. Ichikawa W, Uetake H, Shirota Y, Yamada H, Nishi N, Nihei Z, Sugihara K, Hirayama R: Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expression in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 2003; 9:786-791.
34. Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, Kitajima M, Takechi T, Okabe H, Fukushima M: Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil. Jpn J Cancer Res 2000; 91:105-112.
35. van Triest B, Pinedo HM, Blaaugeers JL, van Diest PJ, Schoenmakers PS, Voorn DA, Smid K, Hoekman K, Hoitsma HF, Peters GJ: Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res 2000; 6:1063-1072.
36. Takenoue T, Nagawa H, Matsuda K, Fujii S, Nita ME, Hatano K, Kitayama J, Tsuruo T, Muto T: Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method. Ann Surg Oncol 2000; 7:193-198.
37. Konno S, Takebayashi Y, Higashimoto M, Katsube T, Kanzaki A, Kawahara M, Takenoshita S, Aiba M, Ogawa K: Thymidine phosphorylase expression in gastric carcinoma as a marker for metastasis. Anticancer Res 2003 23:5011-5014.
38. Nishimura G, Terada I, Kobayashi T, Ninomiya I, Kitagawa H, Fushida S, Fujimura T, Kayahara M, Shimizu K, Ohta T, Miwa K: Thymidine phosphorylase and dihydropyridine dehydrogenase levels in primary colorectal cancer shows a relationship to clinical effect of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy. Oncology Reports 2002; 9:479-482.